scholarly journals Pediatric Inflammatory Bowel Disease

2021 ◽  
Vol 3 (1) ◽  
pp. 11-17
Author(s):  
Rotondo-Trivette S ◽  
Michail S
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Adult Onset ◽  
Future Directions ◽  
Genetic Studies ◽  
Diagnosis And Management ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel ◽  
Pediatric Onset

Inflammatory bowel disease is an important pediatric disease, with as many as 25% of cases presenting during childhood. In this article, we review the types, etiology epidemiology, presentation, diagnosis, and management of pediatric inflammatory bowel disease. We also highlight the unique aspects of pediatric-onset inflammatory bowel disease versus adult-onset and future directions in this field, such as the use of genetic studies and ultrasound for the management of pediatric patients with inflammatory bowel disease.

scholarly journals Mo1767 – Pediatric Onset Inflammatory Bowel Disease is Not Associated with More Disability Compared to Adult Onset Disease

2019 ◽  
Vol 156 (6) ◽  
pp. S-831
Author(s):  
Sherman Picardo ◽  
Remo Panaccione ◽  
Gilaad Kaplan ◽  
Cynthia H. Seow ◽  
Jennifer deBruyn ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Adult Onset ◽  
Inflammatory Bowel ◽  
Pediatric Onset

scholarly journals A133 PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE IS NOT ASSOCIATED WITH MORE DISABILITY COMPARED TO ADULT ONSET DISEASE.

2019 ◽  
Vol 2 (Supplement_2) ◽  
pp. 266-267
Author(s):  
S Picardo ◽  
R Panaccione ◽  
G G Kaplan ◽  
C Seow ◽  
J deBruyn ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Adult Onset ◽  
Inflammatory Bowel ◽  
Pediatric Onset

scholarly journals Vedolizumab: An Emerging Treatment Option for Pediatric Inflammatory Bowel Disease

2021 ◽  
Vol 26 (8) ◽  
pp. 795-801
Author(s):  
Pooja Shah ◽  
Danielle McDonald
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Randomized Trials ◽  
Pediatric Patients ◽  
Pediatric Population ◽  
Case Series ◽  
Pediatric Inflammatory Bowel Disease ◽  
Dosing Regimens ◽  
Inflammatory Bowel

Vedolizumab is a humanized α4β7-integrin antagonist that is currently FDA-approved for adult inflammatory bowel disease. Limited evidence is available to guide use in pediatric patients, though off-label use is described in the form of retrospective reviews and case series. Collectively these publications begin to establish safety and efficacy data in pediatric patients < 18 years of age. Additionally, dosing regimens described in the literature serve to guide weight-based dosing, which is not established at this time. This narrative review aims to summarize the available literature and provide recommendations for vedolizumab use in the pediatric population. A literature search was performed in PubMed (January 2014–December 2020) using the keyword vedolizumab. Based on the available evidence, vedolizumab appears to be a safe and moderately effective agent for treatment of refractory pediatric inflammatory bowel disease. Prospective, randomized trials are warranted to optimize dosing regimens and to establish long-term safety.

Sign in / Sign up

Export Citation Format

Share Document